Quintiles and DaVita Clinical Research Announce Strategic Alliance
Quintiles , the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research , a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader in kidney care, today announced a global strategic alliance. The alliance combines DaVita’s world-class clinical care and expansive footprint of research sites with Quintiles’ industry-leading operational delivery and therapeutic expertise in clinical trials.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005399/en/
“Through this alliance with DaVita Clinical Research, we will have the power to provide biopharmaceutical customers with nephrology expertise and global delivery capabilities to truly advance clinical research,” said Jeanne Hecht, senior vice president and global head, Site and Patient Networks at Quintiles. “Our aim is to align our processes to reduce cycle times and accelerate clinical trial execution. Moreover, we will be able to alleviate the burden on patients participating in renal disease trials by incorporating clinical research into clinical care.”
DaVita Clinical Research is part of DaVita Healthcare Partners, a leading provider of kidney care as well as one of the largest US healthcare providers, providing care to more than one million patients who may be available for potential trial enrollment. DaVita Clinical Research brings to this alliance data-driven trial feasibility expertise, trial sites in Europe and Latin America, its deep clinical knowledge of renal patients as well as an established research infrastructure with DaVita dialysis facilities and 30 years’ experience conducting clinical trials across therapeutic areas.
With progressively complex protocol designs and the increasing demand for broad patient population participation, nephrology clinical studies can pose a series of challenges. Through this strategic alliance, the two companies align to provide capabilities and solutions for overcoming these challenges to deliver end-to-end support for renal disease clinical trials. By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita’s extensive patient understanding, biopharmaceutical customers will be able to take advantage of the combined assets of both companies to progress their clinical programs.
“This alliance allows novel approaches to clinical development and clinical trial execution specifically in site identification, participant enrollment and study design,” said Amy Young, vice president and general manager of DaVita Clinical Research. “We are excited about the opportunities this affords our organizations to provide innovative solutions to the biopharmaceutical industry and the participants we serve.”
Learn more about the strategic alliance between Quintiles and DaVita Clinical Research by visiting www.quintiles.com/library/infographics/quintiles-davita .
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com .
About DaVita HealthCare Partners
DaVita HealthCare Partners Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2016, DaVita Kidney Care operated or provided administrative services at 2,278 outpatient dialysis centers located in the United States serving approximately 180,000 patients. The company also operated 124 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida, Colorado and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2016 HealthCare Partners provided integrated care management for approximately 790,000 patients. For more information, please visit DaVitaHealthCarePartners.com.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) , a wholly owned subsidiary of DaVita HealthCare Partners Inc .,uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, Real World Healthcare Data ,and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com .
Quintiles Media Relations
Phil Bridges, +1-919-998-1653 (office) +1-919-457-6347 (mobile)
Quintiles Investor Relations
DaVita Clinical Research Media Relations
Kate Wilson Strabawa, +1-303-876-7527 (office) +1-720-318-4080 (mobile)
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PA-WESTINGHOUSE-ELECTRIC21.6.2018 22:26 | pressemeddelelse
First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality
PA-WESTINGHOUSE-ELECTRIC21.6.2018 22:09 | pressemeddelelse
Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant
PHARNEXT21.6.2018 20:25 | pressemeddelelse
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 2018
PHILIP-MORRIS-INTERNATIO21.6.2018 20:15 | pressemeddelelse
Philip Morris International Makes Call to Creative, Media and Communications Communities
IBC21.6.2018 18:32 | pressemeddelelse
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats
MENSIA-TECHNOLOGIES21.6.2018 18:25 | pressemeddelelse
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum